TCL.AU

13.52

-0.52%ā†“

BXB.AU

20.37

-1.07%ā†“

COL.AU

20.26

+2.22%ā†‘

QAN.AU

8.59

-2.61%ā†“

CAR.AU

32.73

-1.24%ā†“

TCL.AU

13.52

-0.52%ā†“

BXB.AU

20.37

-1.07%ā†“

COL.AU

20.26

+2.22%ā†‘

QAN.AU

8.59

-2.61%ā†“

CAR.AU

32.73

-1.24%ā†“

TCL.AU

13.52

-0.52%ā†“

BXB.AU

20.37

-1.07%ā†“

COL.AU

20.26

+2.22%ā†‘

QAN.AU

8.59

-2.61%ā†“

CAR.AU

32.73

-1.24%ā†“

TCL.AU

13.52

-0.52%ā†“

BXB.AU

20.37

-1.07%ā†“

COL.AU

20.26

+2.22%ā†‘

QAN.AU

8.59

-2.61%ā†“

CAR.AU

32.73

-1.24%ā†“

TCL.AU

13.52

-0.52%ā†“

BXB.AU

20.37

-1.07%ā†“

COL.AU

20.26

+2.22%ā†‘

QAN.AU

8.59

-2.61%ā†“

CAR.AU

32.73

-1.24%ā†“

Search

CSL Ltd

Gesloten

SectorIndustrieƫn

257.01 0.65

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

250.43

Max

257.24

Belangrijke statistieken

By Trading Economics

Inkomsten

1.3B

2B

Verkoop

1.5B

8.2B

K/W

Sectorgemiddelde

28.972

33.198

EPS

1.831

Dividendrendement

1.7

Winstmarge

24.437

Werknemers

32,698

EBITDA

1.5B

3.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+26.05% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.70%

2.54%

Volgende dividenddatum

9 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-14B

121B

Vorige openingsprijs

256.36

Vorige sluitingsprijs

257.01

Nieuwssentiment

By Acuity

34%

66%

121 / 468 Rangschikking in Industrials

CSL Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 feb 2025, 21:55 UTC

Winsten

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:34 UTC

Winsten

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12 aug 2024, 23:23 UTC

Winsten

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12 aug 2024, 22:49 UTC

Winsten

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

21 mrt 2025, 02:03 UTC

Marktinformatie

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 feb 2025, 22:30 UTC

Marktinformatie

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 feb 2025, 21:40 UTC

Winsten

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:19 UTC

Winsten

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 feb 2025, 21:13 UTC

Winsten

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 feb 2025, 21:12 UTC

Winsten

CSL Interim Dividend US$1.30/Security

10 feb 2025, 21:12 UTC

Winsten

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10 feb 2025, 21:11 UTC

Winsten

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7 nov 2024, 03:53 UTC

Marktinformatie

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22 okt 2024, 22:53 UTC

Marktinformatie

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10 okt 2024, 22:20 UTC

Marktinformatie

CSL Bull Looking for Update on Gross Margin -- Market Talk

13 aug 2024, 00:33 UTC

Marktinformatie

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12 aug 2024, 22:34 UTC

Winsten

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12 aug 2024, 22:18 UTC

Winsten

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12 aug 2024, 22:18 UTC

Winsten

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12 aug 2024, 22:17 UTC

Winsten

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12 aug 2024, 22:16 UTC

Winsten

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12 aug 2024, 22:15 UTC

Winsten

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12 aug 2024, 22:14 UTC

Winsten

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12 aug 2024, 22:13 UTC

Winsten

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12 aug 2024, 22:13 UTC

Winsten

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12 aug 2024, 22:11 UTC

Winsten

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12 aug 2024, 22:10 UTC

Winsten

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12 aug 2024, 22:09 UTC

Winsten

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12 aug 2024, 22:08 UTC

Winsten

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12 aug 2024, 22:07 UTC

Winsten

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Peer Vergelijking

Prijswijziging

CSL Ltd Prognose

Koersdoel

By TipRanks

26.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 317.092Ā AUDĀ  26.05%

Hoogste 360.3Ā AUD

Laagste 250Ā AUD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor CSL Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

12

Buy

2

Hold

0

Sell

Sentiment

By Acuity

121 / 468 Rangschikking in Industrieƫn

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.